54 Participants Needed

A Study of LY3549492 in Healthy Participants

Tm
GW
Overseen ByGene W Voskuhl
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: Eli Lilly and Company

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new drug called LY3549492 to see if it is safe and tolerable for healthy people. Researchers will take blood samples to find out how much of the drug gets into the bloodstream and how the body handles it. The study will last for a few months for each participant.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, since the study is for healthy participants, it's possible that taking certain medications might affect eligibility. It's best to discuss your specific medications with the trial coordinators.

Who Is on the Research Team?

C1

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

Inclusion Criteria

Healthy Males and females (excluding women of childbearing potential at the time of signing the informed consent)
Glycated hemoglobin (HbA1c) value of <6.5% at screening
Body mass index (BMI) within the range 20 to 40 kilograms per square meter (kg/m²), inclusive
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part A

Participants receive LY3549492 as single ascending doses

Approximately 4 weeks

Treatment Part B

Participants receive LY3549492 as multiple ascending doses

Approximately 4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Approximately 4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • LY3549492
  • Placebo
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3549492 (Part B)Experimental Treatment1 Intervention
Group II: LY3549492 (Part A)Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials
2,708
Recruited
3,720,000+
Dr. Daniel Skovronsky profile image

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks profile image

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security